Cancer Research Cancer Epigenetics  EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 42, 496-501, February 1, 1982]
© 1982 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fidler, I. J.
Right arrow Articles by Poste, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fidler, I. J.
Right arrow Articles by Poste, G.

Involvement of Macrophages in the Eradication of Established Metastases following Intravenous Injection of Liposomes Containing Macrophage Activators1

I. J. Fidler2, Z. Barnes, W. E. Fogler, R. Kirsh, P. Bugelski and G. Poste

Cancer Metastasis and Treatment Laboratory, NCI-Frederick Cancer Research Facility, Frederick, Maryland 21701 [I. J. F., Z. B., W. E. F.]; Smith, Kline and French Laboratories, Philadelphia, Pennsylvania 19101 [R. K., P. B., G. P.]; and Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104 [G. P.]

Liposomes containing encapsulated lymphokines or muramyl dipeptide (MDP), when injected i.v. into C57BL/6 mice, produce significant destruction of established lung and lymph node metastases from a s.c. highly metastatic B16-BL6 melanoma. We present evidence that eradication of the metastases is mediated by the activation of host macrophages to the tumoricidal state. Results from three separate types of experiments support this conclusion. (a) When macrophage-activating agents such as lymphokines or MDP were delivered in liposomes that were not efficiently retained in the lung, little or no activation of lung macrophages was observed, and growth of metastases was unaltered. (b) Eradication of metastases was not observed when tumor-bearing animals were treated with agents that impaired macrophage function (e.g., silica, carrageenan, hyperchlorinated drinking water) prior to systemic therapy with liposome-encapsulated lymphokines or liposome-encapsulated MDP. (c) Macrophages activated in vitro by liposome-encapsulated MDP and then injected i.v. into mice bearing experimental lung metastases also significantly inhibited lung metastases. These results suggest that the augmented host response against pulmonary and lymph node metastases generated by the systemic administration of liposome-encapsulated lymphokines or MDP is mediated via activated cytotoxic macrophages.

1 Research sponsored by the National Cancer Institute, Department of Health and Human Services, under Contract NO1-C0-75380 with Litton Bionetics, Inc. and United States Public Health Service Grants CA18260 and CA30192. The contents of this publication do not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the United States Government.

2 To whom requests for reprints should be addressed.

Received 7/27/81. Accepted 10/26/81.




This article has been cited by other articles:


Home page
J. Immunol.Home page
M. R. Jadus, C. C. Williams, M. D. Avina, M. Ly, S. Kim, Y. Liu, R. Narasaki, C. A. Lowell, and H. T. Wepsic
Macrophages Kill T9 Glioma Tumor Cells Bearing the Membrane Isoform of Macrophage Colony Stimulating Factor Through a Phagocytosis-Dependent Pathway
J. Immunol., January 1, 1998; 160(1): 361 - 368.
[Abstract] [Full Text] [PDF]


Home page
Arch SurgHome page
H. E. Wagner, P. Thomas, B. C. Wolf, A. Rapoza, and G. Steele Jr
Inhibition of Sialic Acid Incorporation Prevents Hepatic Metastases
Arch Surg, March 1, 1990; 125(3): 351 - 354.
[Abstract] [PDF]


Home page
Journal of Bioactive and Compatible PolymersHome page
T. Sato, K. Kojima, T.-A. Ihda, J. Sunamoto, and R. M. Ottenbrite
Macrophage Activation by Poly(maleic acid-alt-2-cyclohexyl-1,3-dioxap-5-ene) Encapsulated in Polysaccharide-Coated Liposomes
Journal of Bioactive and Compatible Polymers, October 1, 1986; 1(4): 448 - 460.
[Abstract] [PDF]


Home page
ScienceHome page
W. Koff, I. Fidler, S. Showalter, M. Chakrabarty, B Hampar, L. Ceccorulli, and E. Kleinerman
Human monocytes activated by immunomodulators in liposomes lyse herpesvirus-infected but not normal cells
Science, June 1, 1984; 224(4652): 1007 - 1009.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1982 by the American Association for Cancer Research.